153 related articles for article (PubMed ID: 11418299)
1. Non-myeloablative allogeneic stem cell transplantation focusing on immunotherapy of life-threatening malignant and non-malignant diseases.
Slavin S; Nagler A; Shapira M; Panigrahi S; Samuel S; Or A
Crit Rev Oncol Hematol; 2001; 39(1-2):25-9. PubMed ID: 11418299
[TBL] [Abstract][Full Text] [Related]
2. Non-myeloablative stem cell transplantation and donor lymphocyte infusion for the treatment of cancer and life-threatening non-malignant disorders.
Slavin S; Nagler A; Aker M; Shapira MY; Cividalli G; Or R
Rev Clin Exp Hematol; 2001 Jun; 5(2):135-46. PubMed ID: 11486652
[TBL] [Abstract][Full Text] [Related]
3. Non-myeloablative stem cell transplantation for the treatment of cancer and life-threatening non-malignant disorders; past accomplishments and future goals.
Slavin S; Aker M; Shapira MY; Panigrahi S; Gabriel C; Or R
Transfus Apher Sci; 2002 Oct; 27(2):159-66. PubMed ID: 12350051
[TBL] [Abstract][Full Text] [Related]
4. Nonmyeloablative stem cell transplantation for the treatment of cancer and life-threatening nonmalignant disorders: past accomplishments and future goals.
Slavin S; Or R; Aker M; Shapira MY; Panigrahi S; Symeonidis A; Cividalli G; Nagler A
Cancer Chemother Pharmacol; 2001 Aug; 48 Suppl 1():S79-84. PubMed ID: 11587373
[TBL] [Abstract][Full Text] [Related]
5. Reduced-intensity conditioning for the treatment of malignant and life-threatening non-malignant disorders.
Slavin S; Aker M; Shapira MY; Resnick I; Bitan M; Or R
Clin Transpl; 2003; ():275-82. PubMed ID: 15387119
[TBL] [Abstract][Full Text] [Related]
6. Treatment of leukemia by alloreactive lymphocytes and nonmyeloablative stem cell transplantation.
Slavin S; Nagler A; Shapira MY; Aker M; Gabriel C; Or R
J Clin Immunol; 2002 Mar; 22(2):64-9. PubMed ID: 11998894
[TBL] [Abstract][Full Text] [Related]
7. Donor lymphocyte infusion: the use of alloreactive and tumor-reactive lymphocytes for immunotherapy of malignant and nonmalignant diseases in conjunction with allogeneic stem cell transplantation.
Slavin S; Morecki S; Weiss L; Or R
J Hematother Stem Cell Res; 2002 Apr; 11(2):265-76. PubMed ID: 11983098
[TBL] [Abstract][Full Text] [Related]
8. Nonmyeloablative stem cell transplantation and cell therapy for malignant and non-malignant diseases.
Resnick IB; Shapira MY; Slavin S
Transpl Immunol; 2005 Aug; 14(3-4):207-19. PubMed ID: 15982565
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy of hematologic malignancies and metastatic solid tumors in experimental animals and man.
Slavin S; Morecki S; Weiss L; Or R
Crit Rev Oncol Hematol; 2003 May; 46(2):139-63. PubMed ID: 12711359
[TBL] [Abstract][Full Text] [Related]
10. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
11. Graft vs autoimmunity following allogeneic non-myeloablative blood stem cell transplantation in a patient with chronic myelogenous leukemia and severe systemic psoriasis and psoriatic polyarthritis.
Slavin S; Nagler A; Varadi G; Or R
Exp Hematol; 2000 Jul; 28(7):853-7. PubMed ID: 10907647
[TBL] [Abstract][Full Text] [Related]
12. Non-myeloablative hematopoietic stem cell transplantation (NST) in the treatment of human malignancies: from animal models to clinical practice.
Shimoni A; Nagler A
Cancer Treat Res; 2002; 110():113-36. PubMed ID: 11908195
[TBL] [Abstract][Full Text] [Related]
13. Nonmyeloablative stem cell transplantation: reduced-intensity conditioning for cancer immunotherapy--from bench to patient bedside.
Slavin S; Morecki S; Weiss L; Shapira MY; Resnick I; Or R
Semin Oncol; 2004 Feb; 31(1):4-21. PubMed ID: 14970932
[TBL] [Abstract][Full Text] [Related]
14. Graft-versus-host disease, the graft-versus-leukemia effect, and mixed chimerism following nonmyeloablative stem cell transplantation.
Slavin S
Int J Hematol; 2003 Oct; 78(3):195-207. PubMed ID: 14604277
[TBL] [Abstract][Full Text] [Related]
15. Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.
Gürman G; Arat M; Ilhan O; Konuk N; Beksaç M; Celebi H; Ozcan M; Arslan O; Ustün C; Akan H; Uysal A; Koç H
Cytotherapy; 2001; 3(4):253-60. PubMed ID: 12171713
[TBL] [Abstract][Full Text] [Related]
16. Maternal-fetal relationship, natural chimerism and bilateral transplantation tolerance as the basis for non-myeloablative stem cell transplantation.
Slavin S
Int J Hematol; 2002 Aug; 76 Suppl 1():172-5. PubMed ID: 12430849
[TBL] [Abstract][Full Text] [Related]
17. Allogeneic hematopoietic stem cell transplantation in ovarian carcinoma: results of five patients.
Bay JO; Fleury J; Choufi B; Tournilhac O; Vincent C; Bailly C; Dauplat J; Viens P; Faucher C; Blaise D
Bone Marrow Transplant; 2002 Jul; 30(2):95-102. PubMed ID: 12132048
[TBL] [Abstract][Full Text] [Related]
18. Adoptive allogeneic immunotherapy--history and future perspectives.
Schleuning M
Transfus Sci; 2000 Oct; 23(2):133-50. PubMed ID: 11035275
[TBL] [Abstract][Full Text] [Related]
19. The role of purine analogues in low-intensity regimens with allogeneic hematopoietic stem cell transplantation.
Foss FM
Semin Hematol; 2006 Apr; 43(2 Suppl 2):S35-43. PubMed ID: 16549113
[TBL] [Abstract][Full Text] [Related]
20. Update on non-myeloablative stem cell transplantation for hematologic malignancies.
Giralt S
Int J Hematol; 2002 Aug; 76 Suppl 1():368-75. PubMed ID: 12430884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
